Aethlon Medical
AEMD
25 hedge funds and large institutions have $1.15M invested in Aethlon Medical in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
14% more funds holding
Funds holding: 22 → 25 (+3)
5% more capital invested
Capital invested by funds: $1.09M → $1.15M (+$57.8K)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$604K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$134K |
| 3 |
Renaissance Technologies
New York
|
+$67.5K |
| 4 |
N
Natixis
Paris,
France
|
+$64.9K |
| 5 |
Two Sigma Investments
New York
|
+$60.6K |
Top Sellers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$27K |
| 2 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$11K |
| 3 |
Citigroup
New York
|
-$8K |
AEMD Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q3 2022, worth a combined $1.15M — up 5.3% from $1.09M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AEMD positions and 3 closed out — a net gain of 5 holders — while 7 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $604K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $27K sold.
- 25 institutional investors held Aethlon Medical (AEMD) as of Q3 2022, up from 22 in Q2 2022.
- Funds reported $1.15M of Aethlon Medical stock for Q3 2022, up 5.3% quarter-over-quarter.
- 8 funds opened new Aethlon Medical positions in Q3 2022 and 3 closed out, a net change of +5 holders.
- The largest Aethlon Medical buyer in Q3 2022 was Vanguard Group, an estimated $604K added.
- The largest Aethlon Medical seller in Q3 2022 was Dimensional Fund Advisors, an estimated $27K sold.
Based on aggregated 13F filings for Q3 2022.